{'fraction_non_alphanumeric': 0.03184713375796178, 'fraction_numerical': 0.0074309978768577496, 'mean_word_length': 5.640845070422535, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Efficiency of emoxipine in treatment of multiple organ failure in newborns].

Prospective, placebo-controlled, simple "blind" randomized study of the effect of emoxipine (2-ethyl-6-methyl-3-oxypyridine hydrochloride) on the dynamics of central hemodynamics, content of lipid peroxidation products in tracheo-bronchial lavage, and severity of clinical sickness was performed in newborn children with multiple organ failures (MOF). The obtained results showed that a 10-day course of the intravenous administration of emoxipine in a single dose of 10 mg/kg improved the systolic function of myocardium of left ventricle, limited lipid peroxidation in broncho-pulmonary system, and increased oxygen delivery to tissues. These effects of emoxipine were accompanied by a clinically significant improvement of neurological status, reduction of the need for artificial ventilation of lungs, and decrease of mortality in newborns with MOF diagnosis.